CARM – carisma therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Carisma Therapeutics, Inc. (NASDAQ: CARM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte [Yahoo! Finance]
Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte
Is There An Opportunity With Carisma Therapeutics, Inc.'s (NASDAQ:CARM) 46% Undervaluation? [Yahoo! Finance]
Carisma Therapeutics, Inc. (NASDAQ: CARM) had its price target lowered by analysts at HC Wainwright from $9.00 to $8.00. They now have a "buy" rating on the stock.
Form 10-Q Carisma Therapeutics For: Mar 31
Form 8-K Carisma Therapeutics For: May 09
Form ARS Carisma Therapeutics For: Dec 31
Form DEF 14A Carisma Therapeutics For: Jun 13
Form 8-K Carisma Therapeutics For: Apr 10
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.